Glen Eagle Advisors, LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 2029317
KINGSTON, NJ
Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$32,117
+$22,913 QoQ
Shares Held
2,176
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#159
of 189 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Glen Eagle Advisors, LLC holds $278,065 across 14 Biotechnology names. SLS ranks #4 (11.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
178 | $88,417 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
115 | $71,707 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
200 | $37,456 | |
| 4 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
2,176 | $32,117 | |
| 5 | PRME |
Prime Medicine, Inc.
|
5,000 | $18,450 | |
| 6 | BNTX |
BioNTech SE
|
100 | $9,305 | |
| 7 | GMAB |
Genmab A/S
|
200 | $5,494 | |
| 8 | EXEL |
Exelixis, Inc.
|
89 | $4,842 |
All Filings in SLS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32,117 | 2,176 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,204 | 2,176 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||